All News
Day 3 EULAR Report
Day 3 was an interesting mix of posters, oral presentations, and review sessions on many practical subjects like osteoarthritis, large vessel vasculitis, systemic sclerosis, and pregnancy. Here are a few of my recommended abstracts from Friday at EULAR 2026.
Read Article
Machine learning identifies a “vulnerable” phenotype in older RA patients n=275
-51% “vulnerable”
-Worse grip strength, gait speed & SARC-F
-Higher disability (HAQ 1.56 vs 0.64)
-More fatigue, poorer QoL
-Higher DAS28 despite greater biologic exposure
Suggests we should assess https://t.co/bv1FbTxGKR
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2026 There are over 90 abstracts on CAR-T. Please read my article on a selection of abstracts pertaining to the progress of CAR-T in rheumatic and musculoskeletal diseases @RheumNow
https://t.co/2Uxy3uyF6H https://t.co/VulhEDJTEi
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Depression at RA diagnosis did not predict short-term CV events in a nationwide early RA cohort
-17,669 early RA pts
-7.3% BL depression
-Median follow-up 1.2 years
-No association w/ CV hospitalisation after adjustment (sHR 1.05)
Reassuring short-term data, longer follow-up https://t.co/XmMVGY1VlI
Aurelie Najm AurelieRheumo ( View Tweet)
How many ‘cars’ are there?
crowded #CAR-T ‘driving’ innovation at
#EULAR2026
>90 abstracts w CAR-T in title
Lessons learned
Maybe #immune #reset is not always the goal
➡️vs ’#immune #dimming
How long are effects?
safety looks good
PT selection is key
Early, no damage
@RheumNow https://t.co/6jii5MBJcJ
Links:
Janet Pope Janetbirdope ( View Tweet)
One of the highlights of #EULAR2026 for me:
♀️The "This Is a Woman's World" session
I recapped 8 must-know abstracts (including our work from ARCH_ArLAR) in a new @RheumNow video🎬
https://t.co/3jwJIegGg4 via @YouTube
@ArLARheumatolog https://t.co/Azvkl2sjdu
Links:
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Failure to achieve early remission RA asso w/ non-inflammatory pain
NORD-STAR 526 early RA pts)
no remission at 24 wks increased risk of 48wk
• unacceptable pain (OR ~6)
• refractory pain (OR ~6)
• fibromyalgic RA (OR ~16)
Signal strongest w/ very early remission wk8 https://t.co/H8iyhIrsJw
Aurelie Najm AurelieRheumo ( View Tweet)
Even with tight T2T, ARCTIC 10yr follow-up (n=170) show 9% had RA-ILD on HRCT, plus another 19% with non-specific interstitial findings. Male sex and older age were risk factors. Seropositivity was not. Vigilance remains essential. @RheumNow #EULAR2026 POS1270
Jiha Lee JihaRheum ( View Tweet)
#EULAR2026 Recommendations: Vasculitis
-Confirm diagnosis with imaging and biopsy
- Start GC early but with taper plan
- For major flare again confirm dx and restart GC
- Consider IL-6 or UPA
- MTX may be option if biologics not available
@RheumNow https://t.co/DqLZtW630y
Jiha Lee JihaRheum ( View Tweet)
#EULAR2026 POS1355 A cohort study in Japan identified 5-score predictors of GC-free remission in #lupusnephritis: HCQ, pulsed IV GC, Chronicity index=0, =>75% UPCR reduction by 6mo,& 12 mths CRR. Data cutoff 2024. Interested to see impact of current Combo tx from outset @RheumNow https://t.co/qmpgyEyOOV
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Core definitions when understanding vaccination.
@RheumNow #EULAR2026 https://t.co/wD0iTDxMEx
sheila RHEUMarampa ( View Tweet)
RheumNow’s expanded coverage of #EULAR2026 annual meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.
Dr. John Cush RheumNow ( View Tweet)
Beyond the Scale: Do GLP-1RAs Offer More Than Weight Loss in PsA?
Over 70% of patients with psoriatic arthritis (PsA) struggle with excess weight, amplifying synovio-entheseal inflammation and blunting biologic response.
https://t.co/pAIXkdazci https://t.co/vQTn3BWv2r
Dr. John Cush RheumNow ( View Tweet)
CT imaging in RA
Body composition changes beyond BMI
489 RA vs 397 ctrl
RA asso w/
-increased subcutaneous fat
-increased intermuscular adipose tissue -poorer muscle quality
Looks like it represent “hidden obesity” with more by fat redistribution and myosteatosis
#OP0348
Aurelie Najm AurelieRheumo ( View Tweet)
And now does MRI do better than US at predicting RA progression in at risk pts?
Short answer: No likely too sensitive!
130 anti-CCP+ symptomatic pts
36.9% progressed
BL US positivity predicted progression HR 2.8
MRI showed prevalence of subclinical disease synovitis >80%
Aurelie Najm AurelieRheumo ( View Tweet)
Do probiotics help in #PsA? First RCT (MEDIPSA) says no. Multispecies probiotic vs placebo in 66 pts: 43% vs 65% achieved low disease activity at wk 12 (p=0.167). Gut-joint axis intriguing, but probiotics not the answer yet. @RheumNow #EULAR2026 POS0290
Jiha Lee JihaRheum ( View Tweet)
"It takes about a million dollars to get one AI algorithm approved"
So even after creating an Ai solution, its difficult to actually be able to use it in rheumatology.
@RheumNow #EULAR2026 https://t.co/yX6cT19Sdd
Bella Mehta bella_mehta ( View Tweet)
Detecting subclinica tenosynovitis in pts at risk for RA: who does it better US or DixonMRI?
65 pts RA CSA, US detected only ~23% of cases identified by Dixon
US misses most! But are they “real” tenosynovitis?
MRI (5-min, no contrast) higher sens
US higher spe
Shall we do https://t.co/stsMRdj9eY
Aurelie Najm AurelieRheumo ( View Tweet)
What does remission really mean to patients with #PsA? The RemiPPsA international qualitative study asked 123 patients across 11 countries. Pain-free + ability to resume daily life topped the list, not just composite scores. #EULAR2026 @RheumNow, POS0294 https://t.co/mEGpkewuTX
Jiha Lee JihaRheum ( View Tweet)
#EULAR2026 POS0172 #Lupus arthritis is the most common domain in RCTs but SLEDAI-MSK or BILAG-MSK isn’t satisfactory. Look out for the role out of LAMDA once externally validated using independent trial datasets. 4 candidates: SJC28, ESR, VAS Phy MSK, & VAS Pa Pain @RheumNow https://t.co/QJ51ETLSSN
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
